May 28, 2014 The Canadian Press

Valeant Pharmaceuticals International, Inc. ((TSX:VRX) says it has agreed to sell the rights to five products to Nestle S.A. for $1.4 billion.

Laval, Que.-based Valeant says Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma.

http://www.canadianbusiness.com/business-news/valeant-pharmaceuticals-to-sell-some-assets-to-nestle-for-1-4-billion/